Targeted approaches have revealed frequent epigenetic alterations in ovarian cancer, but the scope and relation of these changes to histologic subtype of disease is unclear. Genome-wide methylation and expression data for 14 clear cell carcinoma (CCC), 32 non-CCC and four corresponding normal cell lines were generated to determine how methylation profiles differ between cells of different histological derivations of ovarian cancer. Consensus clustering showed that CCC is epigenetically distinct. Inverse relationships between expression and methylation in CCC were identified, suggesting functional regulation by methylation, and included 22 hypomethylated (UM) genes and 276 hypermethylated (HM) genes. Categorical and pathway analyses indicated that the CCC-specific UM genes were involved in response to stress and many contain hepatocyte nuclear factor (HNF) 1-binding sites, while the CCC-specific HM genes included members of the estrogen receptor alpha (ERalpha) network and genes involved in tumor development. We independently validated the methylation status of 17 of these pathwayspecific genes, and confirmed increased expression of HNF1 network genes and repression of ERalpha pathway genes in CCC cell lines and primary cancer tissues relative to non-CCC specimens. Treatment of three CCC cell lines with the demethylating agent Decitabine significantly induced expression for all five genes analyzed. Coordinate changes in pathway expression were confirmed using two primary ovarian cancer datasets (p < 0.0001 for both). Our results suggest that methylation regulates specific pathways and biological functions in CCC, with hypomethylation influencing the characteristic biology of the disease while hypermethylation contributes to the carcinogenic process.
Ovarian cancer is the fifth most common cause of cancer death in women 1 and has the worst mortality rate of all gynecologic cancers. 2 Epithelial ovarian cancers are a heterogeneous disease with distinct clinicopathological and molecular features 3 and are classified pathologically into four major histologic subtypes based entirely on tumor cell morphologic criteria: serous adenocarcinoma (SAC), mucinous adenocarcinoma (MAC), endometrioid adenocarcinoma (EAC) and clear cell carcinoma (CCC). Because these histologic subtypes of ovarian cancer have unique clinical characteristics and behavior, histology-specific biomarkers and individualized therapeutic strategies are needed that improve therapeutic options and outcomes. Ovarian CCC is distinct from the other major histologic types of epithelial ovarian cancer 4, 5 and often arises from endometriosis. The clinical outcome of advanced-stage CCC is generally poor and this may be related to the relative resistance to conventional platinum-or taxane-based chemotherapies. [6] [7] [8] Although the different histologic subtypes of ovarian cancer have been associated with genetic defects, such as TP53 mutations in high-grade SAC, PTEN and CTNNBI mutations in EAC and KRAS mutations in MAC, the molecular features of CCC have remained elusive. 9 Recent genome-wide technologies have revealed frequent ARID1A mutations 10, 11 and overexpression of HNF1B 12 in ovarian CCC. We previously identified an ovarian CCC-specific gene signature characterized by activation of the HNF1B pathway. Furthermore, some of these signature genes are regulated by DNA methylation. 13 DNA methylation is an epigenetic mechanism of gene regulation that plays a crucial role in many biological processes including X-chromosome inactivation, genomic imprinting, aging and cancer. 14 In cancer cells, global DNA hypomethylation and aberrant hypermethylation of tumor suppressor genes are well-established mechanisms that contribute to cancer cell transformation. 15 Analysis of individual genes has led to a large number now reported as targets of DNA methylation in ovarian cancer. 1, 16 However, genome-wide methylation profiles may be more instructive because the methylation status of any particular single gene has not been shown to be predictive, diagnostic or prognostic for this disease. 15, 17 Higher resolution elucidation of DNA methylation profiles may lead to the discovery of biomarkers for diagnosis, improved methods of classification and disease monitoring as well as to a better understanding of cancer biology. Although several comprehensive DNA methylation analyses have been reported in ovarian cancer, limitations have included a relatively small number of samples, lack of focus on histological subtypes and in the limited number and selection of genes analyzed. 14, [17] [18] [19] [20] Only four genes (14-3-3 sigma as SFN, PYCARD, WT1 and HNF1B) have been reported as aberrantly methylated in CCC. 1, 13, 16, 21 Therefore, epigenetic features that more fully characterize histological subtypes including CCC have yet to be identified.
In this study, our initial objective was to determine if epigenomic patterns could distinguish the various histologic subtypes of ovarian cancer, including CCC. We identified an ovarian CCC methylation profile that was distinct from the other histologic subtypes of ovarian cancer. Through analysis of genes showing strong associations between DNA methylation and levels of transcription, we identified important biological mechanisms contributing to characteristic features of ovarian CCC 4 that appear to be deregulated through coordinate epigenetic modifications in this disease.
Material and Methods
Detailed methods are provided in Supporting Information.
Cell lines and clinical samples
The immortalized noncancerous cell lines were maintained as described. [22] [23] [24] Ovarian cancer cell lines, including 14 CCC and 32 non-CCC cell lines (Supporting Information Table 1) , were cultured in RPMI1640/FBS/pen-strep medium (SigmaAldrich, St. Louis, MO) with 10% heat-inactivated fetal bovine serum (v/v; Invitrogen, Carlsbad, CA) in an atmosphere of 5% CO 2 at 37 C. The short tandem repeat (STR) genotypes of all ovarian cancer cell lines were analyzed to authenticate the cell lines using either the PowerPlexV R 1. Tissue specimens were derived from 85 patients with ovarian cancer treated at Duke University Medical Center, (13 CCC, 53 SAC, 11 EAC and eight MAC) and from eight patients without malignant disease (four ovarian surface epithelium samples and four fallopian tube epithelium samples). All patients provided written informed consent and specimens were used under a protocol approved by the Duke University Institutional Review Board. For all tumor specimens, representative sections were mounted on slides and stained with hematoxylin and eosin to confirm that at least 60% of the cellular content comprised cancer cells with less than 20% necrosis. Tumors were histologically classified according to World Health Organization (WHO) criteria.
Extraction of genomic DNA and bisulfite treatment
Genomic DNA was extracted from cells cultured in 10-cm dishes to 70-90% confluence using the QIAampV R DNA Mini Kit (Qiagen, Valencia, CA) or from 5 to 20 mg of clinical tissues using the AllPrepV R DNA/RNA/Protein Mini Kit (Qiagen) for methylation beadchip analysis. Puregene Reagents (Qiagen) were used for DNA extraction after Decitabine treatment (see below). Five hundred nanograms of genomic DNA was bisulfite modified using the EZ DNA Methylation TM Kit (Zymo Research, Irvine, CA) according to the manufacturer's protocol for the Infinium methylation assay, and 800 ng of genomic DNA was bisulfite modified using the same kit but according to standard protocol for methylation analysis of individual genes.
Illumina Infinium HumanMethylation BeadChip Assays
Bisulfite-converted genomic DNA was analyzed using the Illumina Infinium HumanMethylation27 BeadChip for cell line samples (GEO Accession Number GSE51688) and HumanMethylation450 Beadchip for clinical tissue specimens (GEO Accession Number GSE51820) (Illumina, San Diego, CA). The HumanMethylation450 BeadChip includes 90% of the content contained on the HumanMethylation27 BeadChip (http:// dl.dropbox.com/u/6904769/50CellLines_b-value_ submission.txt.zip). Chip processing was performed according What's new? Ovarian cancer has several subtypes, and although different genetic mutations have been associated with particular subtypes, the molecular characteristics of ovarian clear cell carcinoma remain hazy. Aberrant DNA methylation can turn cells cancerous, and this study compared patterns of gene methylation in ovarian clear cell carcinomas, other ovarian cancer cells, and normal cells. They found that the clear cell carcinomas could indeed be identified by their distinctive pattern of DNA methylation. They found that this methylation pattern increased expression of certain stress response genes, while other genes, with tumor suppressive functions, were stifled.
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to the manufacturer's protocol by Expression Analysis (Durham, NC), an Illumina Certified Service Provider. Data were extracted using Illumina GenomeStudio v2010.3 software (Illumina). Methylation values for each CpG locus are represented as b-values, a quantitative measure of DNA methylation, with levels ranging from 0 (completely unmethylated) to 1 (completely methylated). Bisulfite conversion efficiency (i.e., the conversion of non-CpG cytosines to uracils) was assessed for all samples by Pyrosequencing (see below) before data generation using the Illumina BeadChips.
Methylation-specific polymerase chain reaction DNA methylation of estrogen receptor alpha (ERalpha) network genes (ESR1, BMP4, DKK1, SOX11, SNCG and MOSC1) was validated using methylation-specific polymerase chain reaction (MS-PCR). Primer sequences and PCR conditions are provided in Supporting Information Table 2a .
Pyrosequencing
All primers for pyrosequencing assays were designed using PSQ assay design software version 1.0.6 (Biotage, Uppsala, Sweden). The pyrosequencing assays were designed such that we analyzed the same CpG sites as those present on the Illumina BeadChip for 11 genes (ESR1, HNF1A, HNF1B, C14orf105, KIF12, MIA2, PAX8, SERPINA6, SGK2, SRC and TM4SF4) and for adjacent CpG sites for the F2 gene. Primer sequences and PCR conditions are shown in Supporting Information Table 2b . Methylation values for each CpG site were calculated using Pyro Q-CpG software 1.0.9 (Biotage).
Real-time reverse transcription-polymerase chain reaction
Two micrograms of total RNA prepared from 36 ovarian cancer cell lines (13 CCC and 23 non-CCC; using RNA Stat60, Teltest, Friendswood, TX) or 49 frozen tissues (13 CCC and 36 non-CCC; using the AllPrepV R DNA/RNA/Protein Mini Kit; Qiagen) were used to generate cDNA in a 40 ml volume with the Superscript II kit (Invitrogen). Two microliters of the cDNA was used as template for PCR using TaqMan assays in a 20 ml volume (Applied Biosystems) for HNF1B (Hs01001602), SGK2 (Hs00367639), C14orf105 (Hs00216847), F2 (Hs01011988), ESR1 (Hs00174860), CRIP1 (Hs00832816), SOX11 (Hs00846583), IGFBP4 (Hs01057900) and BMP4 (Hs00370078). B2M (Hs 00187842) was used as an internal control. Relative expression was calculated using the delta delta Ct method.
5-Aza-2
0 -deoxycytidine (Decitabine) treatment RMG-2, RMG-5 and KOC-7C cell lines were seeded into sixwell plates and the following day they were treated in triplicate by adding RPMI1640/FBS/pen-strep media (mock) or the same media containing 5 mM 5-aza-2 0 -deoxycytidine (Decitabine; Sigma-Aldrich). Media was replaced daily (with/without Decitabine as relevant) for 3 days after which the cells had reached 70-90% confluence and were harvested for DNA extraction as described above or RNA extraction using RNA Stat60 (Teltest).
Real-time reverse transcription (RT)-PCR and pyrosequencing analyses were performed as described above.
Bioinformatics

Identification of genes showing differential methylation.
Identification of genes differentially methylated between groups was done by comparing b-values using unpaired ttests with thresholds of p < 0.01 and difference of average bvalues >0.2 (20% methylation) for the comparison between ovarian cancer cell lines and normal cells or between CCC and non-CCC. Genes annotated by gene name or gene ID (Illumina annotation file) were used for the analyses.
Unsupervised consensus clustering. ConsensusCluster software 25 was used to evaluate the similarity between genes or specimens.
Identification of genes regulated by DNA methylation in ovarian cancer. Two cell line microarray datasets [Gene Expression Omnibus (GEO) Accession Number: GSE25428 and GSE29175 13, 26 were used for the identification of candidate genes whose mRNA expression levels are regulated by DNA methylation in ovarian cancer. The ComBat normalizing algorithm was used before performing any analysis to reduce the likelihood of batch effects. 27 Candidate genes functionally regulated by methylation were identified based on the following criteria: (i) the p-value of unpaired Student t-tests is less than 0.01; (ii) the average b-value difference is more than 0. Categorical analyses. The biological characteristics of the CCC-specific methylation signature were evaluated using the enrichment of Molecular Signatures Database (MSigDB) gene sets (v2.5 updated April 7 2008) 28 with the R package allez 1.0. 29 Briefly, for each gene set, the proportion of the annotated genes in the CCC hypermethylated or hypomethylated gene sets was compared to that for all probeset genes. A gene set was considered significantly enriched if the z-score was more than 4.0. 30 Pathway analyses. The relationship of hypermethylated or hypomethylated genes to particular pathways was evaluated using MetaCore TM software (GeneGo; http://www.genego. com/), an integrated knowledge database and software suite for evaluation of the association between a particular gene list and known pathways.
Heatmap of b-values and expression. Absolute b-values are represented by color gradient intensity, from white; b-value 50, to red; b-value 51, using Java TreeView (http://jtreeview.sourceforge.net/). Average-linkage hierarchical clustering was performed in published expression microarray datasets representing clinical ovarian cancer samples (GSE6008 and
Cancer Genetics
Yamaguchi et al. 31, 32 ) using genes transcriptionally regulated by DNA methylation with Cluster version 3.0 (http://rana.lbl. gov/eisen/).
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Statistical analyses
The Student's t-test was used to compare continuous variables between groups. Fisher's exact test was used for analysis of categorical variables. Correlations between expression microarray values and methylation b-values from the Infinium assay or between b-values and % methylation values from pyrosequencing were evaluated using Pearson's correlation. p-values less than 0.05 were considered statistically significant.
Results
Divergent methylation profiles between ovarian cancer cells and noncancerous cells
By comparing methylation b-values, 2,003 genes (2,561 CpG sites) of a total possible 14,495 genes (27,578 CpG sites) (13.8%) in ovarian cancer cell lines showed methylation levels that differed relative to noncancerous specimens (Supporting Information Table 3 ). Of these differentially methylated genes, 1,870 genes (2,404 CpG sites; 93.4%) were hypermethylated (HM), whereas only 139 genes (157 CpG sites; 7.0%) were hypomethylated (UM) in ovarian cancer cell lines.
In the clinical samples analyzed with the larger probeset, 3,432 genes (6,919 CpG sites) of 21,231 genes (365,860 CpG sites) (16.2%) showed methylation levels that differed compared to normal specimens. Of the differentially methylated genes, 2,383 genes (4,830 CpG sites; 65.6%) were HM, whereas 1,253 genes (2,089 CpG sites; 34.5%) were UM in ovarian cancer tissues (Supporting Information Table 3 ).
CCCs possess a unique methylation profile
Unsupervised consensus clustering generated a distinct CCCspecific cluster in the cell line dataset (Fig. 1a) . The noncancerous cell lines clustered together with nine of 16 SAC (56.3%) cell lines. This data indicates that CCCs possess a distinct epigenomic pattern when compared to the other histologic types of ovarian cancer and noncancerous specimens. Similar to the clustering results in the cell lines, a distinctive CCC-specific cluster was again generated from analysis of clinical specimens. Like the cell lines, 25 of 51 (49.0%) SAC clinical specimens clustered together with normal specimens (Fig. 1b) . Among the tissue specimens, six of eight MAC and five of 11 EAC samples were grouped within the cluster Cancer Genetics containing the majority of the CCC samples. However, both the MAC and EAC subclusters are distinct from the CCC subcluster, indicating that the methylation profiles of MAC and EAC share higher similarity to CCC when compared to the other tissue specimens.
To evaluate the similarity between cell lines and clinical samples, the number of differentially methylated probes that overlap between these datasets was determined among the 25,978 CpG probes in common between the HumanMethylation27 and HumanMethylation450 BeadChips. Of these evaluable CpG probes, 1,042 and 77 CpGs showed hypermethylation in CCC compared to non-CCC cell lines and patient specimens, respectively, with a statistically significant overlap of 25 probes (p < 0.0001). We also found that the cell lines and clinical samples had 54 and 53 CpG probes showing hypomethylation, respectively, in CCC relative to non-CCC, with six CpG probes in common, a finding that is also statistically significant (p < 0.0001). These 25 hypermethylated and six hypomethylated probes are shown in Supporting Information Tables 4a and 4b . These results support that there are specific methylation profiles in cell lines that are also detectable in patient samples.
Identification of genes transcriptionally regulated by DNA methylation in CCC
Next, we examined the biological significance of the CCCspecific DNA methylation. For this purpose, the genes most likely to be transcriptionally regulated by DNA methylation in CCC were identified using cell line data because of the availability of both methylation and expression microarray data and the similarity of methylation status between the cell lines and clinical specimens. First, 856 genes (1,042 CpG sites) showed increased methylation, and 44 genes (54 CpG sites) showed decreased methylation in CCC when compared to non-CCC (Supporting Information Fig. 1a) . Next, potential functional relationships between expression and methylation of the 856 HM and 44 UM CCC genes were assessed by determining if there were correlations between these values. Of 625 evaluable HM genes, 276 genes showed a significant inverse correlation (r < 20.3051, p <0.05) between methylation and expression. Of the 33 evaluable UM genes, 22 showed a significant inverse correlation (r < 20.3217, p < 0.05) between methylation and expression (Supporting Information Fig. 1b) . We considered these 276 HM and 22 UM genes as candidate CCC-specific epigenetically regulated genes (Supporting Information Tables 5a and 5b , respectively).
Hypomethylation of the HNF1 pathway and hypermethylation of estrogen receptor pathway genes in CCC Biological functions of the 22 CCC-specific UM genes were characterized by analyzing the targeted pathways and "biological process" Gene Ontology (GO) terms. Pathway analysis using MetaCore TM indicated that nine of these 22
UM genes (41%) are members of the HNF1 pathway (Fig. 2a) . Furthermore, the nine CCC-specific UM HNF1 pathway genes are not randomly deregulated but rather synchronously altered by methylation in CCC (Fig. 2c) , suggesting that hypomethylation in CCC targets HNF1 pathway genes. Analyses using allez showed significant enrichment of all HNF1-binding motifs among the CCC UM genes including categorical terms V$HNF1_01, RGTTAMWNATT_V$HNF1_01, V$HNF1_Q6 and V$HNF1_C (p < 0.00001; Supporting Information Table 6 ). Allez showed that the 22 CCC UM genes were enriched for stress response-related GO terms including "response to oxidative stress" (z-score > 4.0; Table  1 , top). Among the 276 CCC-specific HM genes, pathway analysis showed that 64 genes were involved in the estrogen receptor pathway (Fig. 2b) . Similar to the synchronous decreased methylation of HNF1 pathway genes in CCC, these 64 genes exhibit coordinate hypermethylation in CCC relative to non-CCC (Fig. 2d) . These results indicate that the estrogen receptor pathway is a target of hypermethylation in CCC. A categorical analysis using allez to identify GO terms associated with the HM genes showed that the 276 genes HM in CCC included many with tumor-suppressive functions having GO annotations of "cell cycle arrest" and "negative regulation of cell cycle," and development-and organogenesis-related genes with annotations of "negative regulation of cytoskeleton organization and biogenesis" ( Table 1 , bottom).
Validation of hypomethylation and increased expression of HNF1 pathway genes in CCC
Eleven hypomethylated genes in the HNF1 pathway (HNF1A, HNF1B, C14orf105, KIF12, MIA2, PAX8, SERPINA6, SGK2, SRC, TM4SF4 and F2) identified through analysis of CCC versus noncancerous specimens and from comparisons between CCC versus non-CCC cell lines were analyzed by bisulfite pyrosequencing. The ten genes for which the same CpG sites were analyzed showed very strong positive correlations between the Infinium assay b-values and the percent methylation as measured by pyrosequencing (r > 0.9605, p < 0.000001 for all genes; Supporting Information Fig. 2 ). Adjacent CpG sites for these same ten genes also showed significant positive correlations between the b-values of the Infinium assay CpG sites and the percent methylation by pyrosequencing, as did the adjacent CpG sites measured for the F2 gene (0.7494< r <0.9906, p < 0.000001 for all genes; Supporting Information Fig. 3 ). Confirming the results of the methylation beadchip analyses, the pyrosequencing results also showed significantly lower methylation levels in CCC relative to those in non-CCC cell lines for these 11 genes (p < 0.01 for all genes; Fig. 3a) . In 85 clinical ovarian cancer specimens, ten of the 11 HNF1 network genes showed overall hypomethylation in ovarian CCC specimens and six of these 11 genes showed significantly decreased methylation in CCC compared to non-CCC (HNF1A, p 5 0.0036; HNF1B, p 5 0.0041; C14orf105, p 5 0.0194; SERPINA6, p 5 0.0291; SRC,
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Yamaguchi et al. MetaCore TM pathway analyses of the 22 CCC-specific UM genes (a) and the 276 CCC-specific HM genes (b), and heatmaps showing methylation profiles of nine HNF1 pathway genes (c) and 64 ERalpha network genes (d) in 46 ovarian cancer cell lines. Of the 22 CCCspecific UM genes for which expression and methylation are inversely correlated, nine were identified as members of the HNF1 transcriptional network (a). Of 276 CCC-specific HM genes for which expression and methylation are inversely correlated, 65 were members of the ERalpha (encoded by ESR1) network (b). In the heatmaps, red to white coloration represents the Infinium b-value from completely methylated to completely unmethylated, respectively. Genes within the HNF1 pathway (c) and ERalpha network (d) show synchronous hypomethylation and hypermethylation, respectively, in CCC versus non-CCC cell lines.
We selected four HNF1B network genes for expression validation studies using both cell lines and clinical specimens. Messenger RNA levels of HNF1B, F2, C14orf105 and SGK2 were significantly increased in 13 CCC cell lines compared to 23 non-CCC cell lines (p 5 0.0018, p 5 0.0057, p 5 0.0046 and p 5 0.0158, respectively; Fig. 4a ). Clinical samples also showed higher expression for all four genes comparing CCC (N 5 13) to non-CCC (N 5 36) specimens (HNF1B, p 5 0.0002; F2, p < 0.0001; C14orf105, p 5 0.0002 and SGK2, p 5 0.0019; Fig. 4b ).
We used publicly available ovarian cancer expression microarray datasets representing clinical ovarian cancer samples (GSE6008 and GSE2109) to assess the expression levels of the genes we had identified as functionally regulated by methylation. Supervised hierarchical clustering was performed using only the genes regulated by DNA methylation listed in Supporting Information Tables 5a and 5b. The CCC specimens were clearly divided from non-CCC samples based on the expression levels of these genes. The CCC-specific UM genes from our analysis were enriched among a distinct cluster of genes that are highly expressed in the CCC clinical specimens when compared to the presence of CCC-specific HM genes in this cluster (16 of 30 versus 0 of 378 in GSE6008, and 18 of 30 versus 1 of 378 in GSE2109; p < 0.0001 for both; Supporting Information Figs. 4a and 4b) . 2 GO terms related to stress response. 3 GO terms related to development and organogenesis. 4 GO terms related to tumor suppression.
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analyzed. We also investigated these six genes in clinical specimens, and three of the six (SOX11, BMP4 and MOCS1) were methylated more often in CCC than in non-CCC, with SOX11 showing a significant difference (p 5 0.0116) and BMP4 and MOCS1 approaching significance (p 5 0.0645 and 0.1784, respectively; Table 2 , bottom and Supporting Information Figs. 6a-6f).
Transcript levels for five ER pathway genes (ESR1, CRIP1, SOX11, IGFBP4 and BMP4) were decreased in CCC cell lines when compared to non-CCC cell lines, all of which were significant except for SOX11 (p 5 0.0112, p 5 0.0046, p 5 0.2108, p 5 0.0038 and p 5 0.0472, respectively; Fig. 4a ). Among the clinical specimens, four genes showed lower average expression levels in CCC compared to non-CCC, with a The potential to reactivate expression of five genes, ESR1, CRIP1, SOX11, IGFBP4 and BMP4, was evaluated in three CCC cell lines (RMG-2, RMG-5 and KOC-7C) using the DNA methyltransferase inhibitor, 5-aza-2 0 -deoxycytidine (Decitabine). There was a marked and significant increase in mRNA levels for all five genes in cells treated with Decitabine 
relative to the mock-treated cells (Fig. 4c) . We examined the methylation status of ESR1 in these same cell lines and showed that in each case, methylation was significantly decreased following Decitabine treatment relative to mocktreated cells (p 0.01; Fig. 4d ). Altogether, these results support a functional relationship between DNA methylation and transcriptional activity that is deregulated in CCC.
Discussion
Recent genome-wide technologies have provided opportunities to develop profiles that can distinguish, identify and classify discrete disease subsets as well as predict outcome or the response to therapy. Although ovarian cancer is a morphologically and biologically heterogeneous disease, these approaches have enabled classification of ovarian cancers into distinct subtypes. 2, 31, 33, 34 However, there is a paucity of genome-wide methylation data to examine if epigenomic patterns discriminate histological subtypes of cancers, including ovarian cancer.
The comparison of methylation profiles between ovarian cancer and noncancerous cells indicated that of the 2,003 genes that showed differential levels of methylation, as many as 93.4% showed hypermethylation in the cancer cell lines. Based on prior focused studies of promoter CpG island methylation and next-generation sequencing, acquisition of methylation occurs more frequently than loss of methylation in almost all types of primary tumors when compared to their normal counterparts. 35, 36 Because 26,956 (97.7%) of the 27,578 CpG sites are located at promoter regions on the Illumina Infinium HumanMethylation27 BeadChip, our results are comparable with those of published reports. The ratio of HM genes (65.5%) in primary cancer tissues was smaller than that in cell lines probably owing to the inclusion of CpG sites for all known genes as well as intergenic CpG sites (485,577 CpG sites) in addition to the relative heterogeneity of cell types present within clinical specimens.
Consensus clustering identified a CCC-specific cluster and a cluster comprised of noncancerous cells together with approximately half of the SAC both in cell lines and clinical samples. In the clinical specimens, MAC and some of the EAC formed subclusters with the CCC clinical specimens, indicating closer similarity to CCC when compared with the other tissues analyzed with respect to DNA methylation. These results suggest that CCC, MAC and some EAC acquire distinct methylation profiles, which may in part reflect differences in the carcinogenic process for the different histologic types of ovarian cancer. For example, high-grade SAC and EAC are thought to arise de novo (type 2 ovarian cancer), whereas CCC and MAC are thought to arise from precursor benign cysts, indicating an adenoma-carcinoma sequence (type 1 ovarian cancer). 37 These differences in carcinogenic steps may be brought about by or affect specific epigenetic patterns. 38 Differences in genome-wide methylation status between histologic subtypes of ovarian cancer have been controversial. Although single genes (14-3-3 sigma also known PYCARD, WT1 and HNF1B) have been reported as showing aberrant methylation in CCC, 1, 13, 16, 21 comprehensive methylation analyses showed that differentially methylated genes in CCC overlap with SAC and EAC. 14, 39 However, these studies were limited in their analysis to 1,505 CpG loci selected from 871 genes (GoldenGate Methylation Cancer Panel I) and analyzed a small number of CCC samples (only three and four specimens, respectively). Our study found altered methylation in CCC for three of four genes that are known as epigenetically regulated in CCC (14-3-3 sigma PYCARD, WT1 and HNF1B), whereas the prior studies did not identify hypomethylation of HNF1B network genes. Furthermore, Houshdaran et al.
14 identified hypermethylation of ESR1 and WT1 genes in CCC, and Yoon et al. 39 did not identify these genes. Our study is the first that has begun to resolve these limitations with the identification of specific methylation profiles that distinguish the histologic subtypes, especially ovarian CCC, suggesting that epigenetic regulation contributes to the ontogeny of epithelial ovarian cancer.
Although many single genes have been reported as regulated by DNA methylation in ovarian cancer, the biological role of genome-wide methylation in ovarian carcinogenesis has not been elucidated, with questions remaining as to whether or not changes in methylation reflect cause or consequence. We considered the genes showing an inverse correlation between expression and methylation as functionally important genes that are regulated at least in part through epigenetic mechanisms. For our purposes, the data from cell lines were used to evaluate expression-methylation correlations and proved more powerful at revealing these relationships than the clinical samples, likely because of the heterogeneity in cell type composition of the clinical tissue showed that genes with HNF1 transcription factor-binding sites as well as HNF1B were synchronously hypomethylated in CCC. Furthermore, genes that function in the ERalpha network in CCC were among the 276 HM genes, including ESR1 and WT1. These findings suggest that hypomethylation and hypermethylation in CCC appear to target genes belonging to specific and highly relevant pathways in this particular histologic subtype of ovarian cancer. Previously, we reported that HNF1 transcription is activated in CCC relative to the other ovarian cancer histologic subtypes, and this activation is related to loss of DNA methylation at HNF1B. 13, 21, 40 Our finding that activation occurs of multiple components of the HNF1 pathway by synchronous hypomethylation is a significant step forward in understanding this process and supports previous studies. HNF1B is involved in glucose homeostasis and may be responsible for the prominence of glycogen in CCC cells 41, 42 causing the cytoplasm to be clear in appearance, a defining feature of CCC. Our findings suggest that this morphologic feature of CCC is at least in part epigenetically regulated. Ovarian CCC is characterized by unique biology, including slow growth and resistance to chemotherapy and oxidative stress. Ovarian CCC also exhibits the molecular phenotypes of HNF1 pathway activation, PI3K pathway activation and MAPK activation, traits that have been collectively referred to as "ovarian CCC-likeness." 4 Using GO term analysis, CCC-specific UM genes were enriched with genes related to oxidative stress, consistent with "ovarian CCC-likeness." These results indicate that loss of DNA methylation appears to target specific pathways and biological functions, with hypomethylation influencing pathways that help sculpt the characteristic biology of the disease.
ESR1, which is a key molecule in the ERalpha network that we found is hypermethylated in ovarian CCC, is a known target of methylation, and the absence of ERalpha expression in CCC has been reported. [43] [44] [45] WT1, one of the genes regulated by ERalpha signaling, has previously been shown to be inactivated by promoter methylation in ovarian CCC. 46 These results support our findings and underscore the importance of epigenetic regulation of this pathway in CCC. Endometriotic cysts of the ovary are precursors of ovarian cancer, especially of the CCC and EAC histologic subtypes. 4 Akahane et al. showed that reductions in ERalpha expression occurred with progression from endometriosis to atypical endometriosis in CCC specimens, whereas ERalpha expression increased with malignant transformation in EAC. 47 Estrogen signaling through estrogen receptors has divergent outcomes in that it can induce activation of cell proliferation but also inhibit cell cycle progression. 48, 49 Our results indicate that the ERalpha signaling-independent growth of CCC is largely attributable to aberrant epigenetic alterations in CCC. Although changes in CCC phenotype cannot be specifically assessed using demethylating agents, these findings support our hypothetical model for the malignant transformation of endometriosis, in which EAC is induced by estrogen and CCC is influenced by the unique microenvironment within endometriotic cysts, including persistent exposure to oxidative stress and chronic inflammation. 4 Epigenetic changes can be the earliest initiation factor and complement single driver mutations in a human cancer; 50 our results suggest that coordinate deregulation of DNA methylation leads not only to tumor development but also defines the biological features of the malignancy.
We previously reported suppression of TGFbeta pathway activity by DNA methylation in ovarian cancers, primarily of serous histology, 26 while our study demonstrates that there are distinct pathways influenced by hypomethylation and hypermethylation in ovarian CCC. Genetic and epigenetic disruption plays a fundamental role in cancer development. However, mutations in ARID1A and PIK3CA are the only genetic alterations that have been identified in 50% and 40% of CCC cases, respectively. Thus, gene mutations alone cannot distinguish histologic subtypes of ovarian cancer. Our results indicate that coordinate changes in DNA methylation occur that affect expression of genes belonging to specific and relevant pathways in ovarian CCC, which contrasts with the more isolated pattern of genetic mutations observed in this disease. In high-grade SAC, TP53 mutations initiate carcinogenesis and also contribute to the rapid growth that characterizes this histologic subtype, a "genetically based disposition." On the other hand, ARID1A mutations lead to malignant transformation from endometriosis to CCC and the specific biological characteristics of CCC and "ovarian CCC-likeness" are developed through alteration of DNA methylation, an "epigenetically based disposition." Furthermore, although changes in methylation levels induced by environmental stress such as oxidative stress and inflammation were not analyzed in this study, our current and prior results collectively suggest that CCC tumor development is brought about by microenvironment-mediated effects resulting from oxidative stress that lead to these CCC-specific methylation profiles. 13 Inflammatory diseases such as ulcerative colitis and chronic gastritis resulting from Helicobacter pylori infection induce increased DNA methylation and are associated with increased cancer risk. 51 Together, these findings suggest that an "epigenetically based disposition" may be involved in inflammation-induced carcinogenesis.
In summary, our genome-wide methylation analyses have revealed that ovarian CCC has a distinct methylation profile relative to the other histological subtypes of epithelial ovarian cancer. The CCC-specific methylation profile includes synchronous gain of promoter methylation for multiple genes in the ERalpha pathway and loss of promoter methylation for multiple genes in the HNF1 pathway. Further work will be required to more precisely delineate the functions of these two pathways in this disease, to develop these changes as epigenetic biomarkers and to explore new modalities of treatment for CCC, including epigenetic therapies.
